Aslam Anis
Academic Rank(s)
Professor
Director, School of Population and Public Health
Director, Centre for Advancing Health Outcomes
Phone
604-806-8712
604-822-2772
spph.director@ubc.ca
Location
135 – 2206 East Mall Vancouver, BC V6T 1Z3
Research Area: cost effectiveness of AIDS treatments; drug assessments – pharmacoeconomics; health care economics; health regulations, Health economics, rhematoid arthritis, biologic therapies
Dr. Aslam Anis is one of Canada’s most distinguished health economists. In a career spanning more than 30 years, he has achieved international recognition for his seminal contributions to the fields of pharmacoeconomics, pharmaceutical industry regulation, and drug pricing. Dr. Anis’ current and past work is influential across a broad spectrum of health research domains including HIV/AIDS, rheumatoid arthritis, substance use and addiction treatment, among others. He has published over 250 peer-reviewed manuscripts and regularly presents at national and international conferences as an expert in his field.
Dr. Anis has also developed a reputation for leadership and administrative excellence. He is a key architect for the continuing success of the Canadian HIV Trials Network (CTN) and the Centre for Advancing Health Outcomes, where he has made remarkable contributions to the health sciences and further established himself as one of the pre-eminent health economists in Canada and internationally.
2010: Fellow of the Canadian Academy of Health Scientists
2022: Faculty of Medicine Distinguished Researcher Award
National Director, CIHR Canadian HIV Trials Network
Director, School of Population and Public Health, UBC
Senior Scientist, Arthritis Research Canada
Centre Director, Centre for Advancing Health Outcomes
- Cost-effectiveness of new drugs
- Impact of regulations on the pharmaceutical industry
- HIV/AIDS
- Arthritis
- ObesityHis primary areas of research involvement include health services research, measuring patient-reported outcomes, clinical trials including pragmatic and pharmacoeconomic trials, Canadian competition policy in the pharmaceutical industry, and the cost-effectiveness of treatments for HIV/AIDS, rheumatoid arthritis, and other conditions.
SPPH 546: Introduction to Health Economics